298 related articles for article (PubMed ID: 27775076)
21. Neuroendocrine differentiation distinguishes basaloid variant of lung squamous cell carcinoma.
Keyhanian K; Phillips WJ; Yeung BS; Gomes M; Lo B; Sekhon HS
Diagn Pathol; 2022 May; 17(1):46. PubMed ID: 35538551
[TBL] [Abstract][Full Text] [Related]
22. Somatic mutations of signaling genes in non-small-cell lung cancer.
Sanders HR; Albitar M
Cancer Genet Cytogenet; 2010 Nov; 203(1):7-15. PubMed ID: 20951313
[TBL] [Abstract][Full Text] [Related]
23. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
Kayser G
Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
[TBL] [Abstract][Full Text] [Related]
24. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
25. Genomics of squamous cell lung cancer.
Rooney M; Devarakonda S; Govindan R
Oncologist; 2013 Jun; 18(6):707-16. PubMed ID: 23728941
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
[TBL] [Abstract][Full Text] [Related]
27. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis.
Solomides CC; Evans BJ; Navenot JM; Vadigepalli R; Peiper SC; Wang ZX
Acta Cytol; 2012; 56(6):645-54. PubMed ID: 23207443
[TBL] [Abstract][Full Text] [Related]
29. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
Walter K; Holcomb T; Januario T; Du P; Evangelista M; Kartha N; Iniguez L; Soriano R; Huw L; Stern H; Modrusan Z; Seshagiri S; Hampton GM; Amler LC; Bourgon R; Yauch RL; Shames DS
Clin Cancer Res; 2012 Apr; 18(8):2360-73. PubMed ID: 22261801
[TBL] [Abstract][Full Text] [Related]
31. Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection.
Zheng H; Zhan Y; Zhang Y; Liu S; Lu J; Yang Y; Wen Q; Fan S
Cancer Med; 2019 Nov; 8(16):6894-6903. PubMed ID: 31560169
[TBL] [Abstract][Full Text] [Related]
32. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
33. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.
Lockwood WW; Chari R; Coe BP; Thu KL; Garnis C; Malloff CA; Campbell J; Williams AC; Hwang D; Zhu CQ; Buys TP; Yee J; English JC; Macaulay C; Tsao MS; Gazdar AF; Minna JD; Lam S; Lam WL
PLoS Med; 2010 Jul; 7(7):e1000315. PubMed ID: 20668658
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations defining NSCLC subtypes and their therapeutic implications.
Pikor LA; Ramnarine VR; Lam S; Lam WL
Lung Cancer; 2013 Nov; 82(2):179-89. PubMed ID: 24011633
[TBL] [Abstract][Full Text] [Related]
35. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes.
Yang J; Lin J; Liu T; Chen T; Pan S; Huang W; Li S
Lung Cancer; 2014 Aug; 85(2):110-5. PubMed ID: 24906504
[TBL] [Abstract][Full Text] [Related]
36. Integrated molecular portrait of non-small cell lung cancers.
Lazar V; Suo C; Orear C; van den Oord J; Balogh Z; Guegan J; Job B; Meurice G; Ripoche H; Calza S; Hasmats J; Lundeberg J; Lacroix L; Vielh P; Dufour F; Lehtiö J; Napieralski R; Eggermont A; Schmitt M; Cadranel J; Besse B; Girard P; Blackhall F; Validire P; Soria JC; Dessen P; Hansson J; Pawitan Y
BMC Med Genomics; 2013 Dec; 6():53. PubMed ID: 24299561
[TBL] [Abstract][Full Text] [Related]
37. Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC.
Halvorsen AR; Ragle Aure M; Õjlert ÅK; Brustugun OT; Solberg S; Nebdal D; Helland Å
Mol Oncol; 2019 Dec; 13(12):2604-2615. PubMed ID: 31505091
[TBL] [Abstract][Full Text] [Related]
38. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.
Chen K; Shang Z; Dai AL; Dai PL
Life Sci; 2020 Aug; 255():117816. PubMed ID: 32454155
[TBL] [Abstract][Full Text] [Related]
39. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
40. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
